PHG enters its May 6 earnings report with options traders having pivoted dramatically toward bullish positioning — a contrast that makes the print unusually charged.
The clearest signal is the put/call ratio. It has collapsed to 0.46, roughly 1.2 standard deviations below its 20-day mean of 0.78 and near the lowest reading in the past year. Through most of March and into mid-April, the PCR held above 1.05 — consistent, defensive hedging. Then it broke sharply lower after April 17, landing close to the 52-week low of 0.46. That is a textbook shift from hedged to net-bullish options positioning. The move happened even as the stock lost nearly 5% over the past month to close at $26.16, down another 0.7% on Friday. Options traders are leaning into the print rather than away from it.
Short interest is not the story here. The estimated borrow market for PHG remains shallow — with days to cover at just 2.2 and borrow costs running at a modest 0.54% APR, there is no meaningful squeeze dynamic. Short shares did pick up roughly 16% over the past week, but remain well within a range that has been contracting over the past month. Availability in the lending pool is ample, and the ORTEX short score of 36.7 places PHG in the bottom third of the universe on short pressure. The lending market is quiet.
The debate heading into the print centres on whether Philips' medical imaging and patient monitoring recovery is accelerating at a pace that justifies re-rating. Bulls can point to an FDA 510(k) clearance secured this week for a new Smart Fit MRI coil — a signal the product pipeline is moving. The February earnings print produced an 8.3% one-day gain, and the stock held most of that ground over the following five days. Institutional ownership tells a broadly supportive story: Lingotto Investment Management — the Agnelli family office — holds 19.2% of shares with no recent change, while BlackRock added roughly 2.2 million shares as recently as April 27. The valuation is undemanding: the stock trades at 13.8x trailing earnings with an EV/EBITDA of 8.3x, both compressing gently over the past month. Bears will note the stock remains well off prior peaks and that a fresh field safety notice from Germany's BfArM covering Allura Xper and Azurion imaging systems — issued May 2 — adds a regulatory overhang into the release.
The May 6 print will test whether the sharp options sentiment shift was prescient, or whether the product and regulatory picture is murkier than call buyers are pricing in.
See the live data behind this article on ORTEX.
Open PHG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
